Financials data is unavailable for this security.
View more
Year on year Fusen Pharmaceutical Co Ltd 's revenues fell -42.36% from 565.61m to 326.03m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 36.28m to a larger loss of 188.78m.
| Gross margin | 41.39% |
|---|---|
| Net profit margin | -72.61% |
| Operating margin | -21.23% |
| Return on assets | -13.62% |
|---|---|
| Return on equity | -40.36% |
| Return on investment | -32.04% |
More ▼
Cash flow in CNYView more
In 2024, cash reserves at Fusen Pharmaceutical Co Ltd fell by 13.79m. However, the company earned 133.73m from its operations for a Cash Flow Margin of 41.02%. In addition the company generated 15.99m cash from financing while 163.42m was spent on investing.
| Cash flow per share | -0.2015 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.5303 |
|---|---|
| Tangible book value per share | 0.4905 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.5681 |
|---|---|
| Quick ratio | 0.4241 |
| Total debt/total equity | 1.05 |
|---|---|
| Total debt/total capital | 0.5137 |
More ▼
Growth rates in CNY
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -96.81 |
